Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for HMB-002 in Von Willebrand disease (VWD). The expected timing is based on the latest available company guidance and may change.
05/21/26:- HMB-002 Ph1/2 ongoing in VWD; data expected late 2026 or early 2027. 06/26/26:- First-in-human Ph1/2 data showed VWF and FVIII increases; multiple-dose assessment ongoing. 07/12/26:- SAD data showed ≥2.4-fold VWF/FVIII rise; Ph1/2 readout still expected Late 2026/Early 2027. 08/11/26:- VELORA Pioneer Ph1/2 data showed VWF/FVIII increases; additional data expected Late 2026/Early 2027.
Verification
Confirm timing and program details against the company announcement or filing.